Effects of Vitamin D 3 supplementation on epigenetic aging in overweight and obese african americans with suboptimal Vitamin D status

A randomized clinical trial

Li Chen, Yanbin Dong, Jigar Bhagatwala, Anas Raed, Ying Huang, Haidong Zhu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background We have previously shown that vitamin D supplementation increases telomerase activity, suggesting an anti-aging effect. In this study, we aim to test the hypothesis that vitamin D supplementation would slow down epigenetic aging, a new marker of biological aging. Methods A randomized clinical trial was previously conducted among 70 overweight/obese African Americans with serum 25-hydroxyvitamin D [25(OH)D] < 50 nmol/L, who were randomly assigned into four groups of 600 IU/d, 2,000 IU/d, 4,000 IU/d of vitamin D 3 supplements or placebo followed by 16-week interventions. Whole genome-wide DNA methylation analysis was conducted in 51 participants. DNA methylation ages were calculated according to the Horvath and the Hannum methods. Methylation-based age acceleration index (ΔAge) is defined as the difference between DNA methylation age and chronological age in years. Mixed-effects models were used to evaluate the treatment effects. Results Fifty-one participants (aged 26.1 ± 9.3 years, 16% are male) were included in the study. After the adjustment of multi-covariates, vitamin D 3 supplementation of 4,000 IU/d was associated with 1.85 years decrease in Horvath epigenetic aging compared with placebo (p value =.046), and 2,000 IU/d was associated with 1.90 years decrease in Hannum epigenetic aging (p value =.044). Serum 25(OH)D concentrations were significantly associated with decreased Horvath ΔAge only (p values =.002), regardless of treatments. Conclusions Our results suggest that vitamin D supplementation may slow down Horvath epigenetic aging. But the effect on Hannum epigenetic aging is not conclusive. Large-scale and longer duration clinical trials are needed to replicate the findings.

Original languageEnglish (US)
Pages (from-to)91-98
Number of pages8
JournalJournals of Gerontology - Series A Biological Sciences and Medical Sciences
Volume74
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Cholecalciferol
Epigenomics
Vitamin D
African Americans
Randomized Controlled Trials
DNA Methylation
Placebos
Telomerase
Serum
Methylation
Clinical Trials
Genome
Therapeutics

Keywords

  • 25-hydroxyvitamin D
  • DNA methylation age
  • Vitamin D insufficiency

ASJC Scopus subject areas

  • Aging
  • Geriatrics and Gerontology

Cite this

@article{72532af88e6949fd85cb0b865450c80b,
title = "Effects of Vitamin D 3 supplementation on epigenetic aging in overweight and obese african americans with suboptimal Vitamin D status: A randomized clinical trial",
abstract = "Background We have previously shown that vitamin D supplementation increases telomerase activity, suggesting an anti-aging effect. In this study, we aim to test the hypothesis that vitamin D supplementation would slow down epigenetic aging, a new marker of biological aging. Methods A randomized clinical trial was previously conducted among 70 overweight/obese African Americans with serum 25-hydroxyvitamin D [25(OH)D] < 50 nmol/L, who were randomly assigned into four groups of 600 IU/d, 2,000 IU/d, 4,000 IU/d of vitamin D 3 supplements or placebo followed by 16-week interventions. Whole genome-wide DNA methylation analysis was conducted in 51 participants. DNA methylation ages were calculated according to the Horvath and the Hannum methods. Methylation-based age acceleration index (ΔAge) is defined as the difference between DNA methylation age and chronological age in years. Mixed-effects models were used to evaluate the treatment effects. Results Fifty-one participants (aged 26.1 ± 9.3 years, 16{\%} are male) were included in the study. After the adjustment of multi-covariates, vitamin D 3 supplementation of 4,000 IU/d was associated with 1.85 years decrease in Horvath epigenetic aging compared with placebo (p value =.046), and 2,000 IU/d was associated with 1.90 years decrease in Hannum epigenetic aging (p value =.044). Serum 25(OH)D concentrations were significantly associated with decreased Horvath ΔAge only (p values =.002), regardless of treatments. Conclusions Our results suggest that vitamin D supplementation may slow down Horvath epigenetic aging. But the effect on Hannum epigenetic aging is not conclusive. Large-scale and longer duration clinical trials are needed to replicate the findings.",
keywords = "25-hydroxyvitamin D, DNA methylation age, Vitamin D insufficiency",
author = "Li Chen and Yanbin Dong and Jigar Bhagatwala and Anas Raed and Ying Huang and Haidong Zhu",
year = "2019",
month = "1",
day = "1",
doi = "10.1093/gerona/gly223",
language = "English (US)",
volume = "74",
pages = "91--98",
journal = "Journals of Gerontology - Series A Biological Sciences and Medical Sciences",
issn = "1079-5006",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Effects of Vitamin D 3 supplementation on epigenetic aging in overweight and obese african americans with suboptimal Vitamin D status

T2 - A randomized clinical trial

AU - Chen, Li

AU - Dong, Yanbin

AU - Bhagatwala, Jigar

AU - Raed, Anas

AU - Huang, Ying

AU - Zhu, Haidong

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background We have previously shown that vitamin D supplementation increases telomerase activity, suggesting an anti-aging effect. In this study, we aim to test the hypothesis that vitamin D supplementation would slow down epigenetic aging, a new marker of biological aging. Methods A randomized clinical trial was previously conducted among 70 overweight/obese African Americans with serum 25-hydroxyvitamin D [25(OH)D] < 50 nmol/L, who were randomly assigned into four groups of 600 IU/d, 2,000 IU/d, 4,000 IU/d of vitamin D 3 supplements or placebo followed by 16-week interventions. Whole genome-wide DNA methylation analysis was conducted in 51 participants. DNA methylation ages were calculated according to the Horvath and the Hannum methods. Methylation-based age acceleration index (ΔAge) is defined as the difference between DNA methylation age and chronological age in years. Mixed-effects models were used to evaluate the treatment effects. Results Fifty-one participants (aged 26.1 ± 9.3 years, 16% are male) were included in the study. After the adjustment of multi-covariates, vitamin D 3 supplementation of 4,000 IU/d was associated with 1.85 years decrease in Horvath epigenetic aging compared with placebo (p value =.046), and 2,000 IU/d was associated with 1.90 years decrease in Hannum epigenetic aging (p value =.044). Serum 25(OH)D concentrations were significantly associated with decreased Horvath ΔAge only (p values =.002), regardless of treatments. Conclusions Our results suggest that vitamin D supplementation may slow down Horvath epigenetic aging. But the effect on Hannum epigenetic aging is not conclusive. Large-scale and longer duration clinical trials are needed to replicate the findings.

AB - Background We have previously shown that vitamin D supplementation increases telomerase activity, suggesting an anti-aging effect. In this study, we aim to test the hypothesis that vitamin D supplementation would slow down epigenetic aging, a new marker of biological aging. Methods A randomized clinical trial was previously conducted among 70 overweight/obese African Americans with serum 25-hydroxyvitamin D [25(OH)D] < 50 nmol/L, who were randomly assigned into four groups of 600 IU/d, 2,000 IU/d, 4,000 IU/d of vitamin D 3 supplements or placebo followed by 16-week interventions. Whole genome-wide DNA methylation analysis was conducted in 51 participants. DNA methylation ages were calculated according to the Horvath and the Hannum methods. Methylation-based age acceleration index (ΔAge) is defined as the difference between DNA methylation age and chronological age in years. Mixed-effects models were used to evaluate the treatment effects. Results Fifty-one participants (aged 26.1 ± 9.3 years, 16% are male) were included in the study. After the adjustment of multi-covariates, vitamin D 3 supplementation of 4,000 IU/d was associated with 1.85 years decrease in Horvath epigenetic aging compared with placebo (p value =.046), and 2,000 IU/d was associated with 1.90 years decrease in Hannum epigenetic aging (p value =.044). Serum 25(OH)D concentrations were significantly associated with decreased Horvath ΔAge only (p values =.002), regardless of treatments. Conclusions Our results suggest that vitamin D supplementation may slow down Horvath epigenetic aging. But the effect on Hannum epigenetic aging is not conclusive. Large-scale and longer duration clinical trials are needed to replicate the findings.

KW - 25-hydroxyvitamin D

KW - DNA methylation age

KW - Vitamin D insufficiency

UR - http://www.scopus.com/inward/record.url?scp=85058764874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058764874&partnerID=8YFLogxK

U2 - 10.1093/gerona/gly223

DO - 10.1093/gerona/gly223

M3 - Article

VL - 74

SP - 91

EP - 98

JO - Journals of Gerontology - Series A Biological Sciences and Medical Sciences

JF - Journals of Gerontology - Series A Biological Sciences and Medical Sciences

SN - 1079-5006

IS - 1

ER -